Top Markets
#1 Derive Derive +32.37%
#2 Cross Cross +15.42%
#3 Glidr Glidr +10.10%
#4 Gama Token Gama Token +9.10%
#5 Steakhouse ETH Morpho Vault Steakhouse ETH Morpho Vault +6.92%
#6 Palladium Network Palladium Network +6.09%
#7 Based Based +5.99%
#8 Geodnet Geodnet +5.11%
#9 龙虾 (Lobster) 龙虾 (Lobster) +5.09%
#10 Talus Network Talus Network +4.83%
Coin of the day
Derive Derive
設定
言語
日本
通貨
USD
テーマ
Delota Corp. Delota Corp.

Delota Corp.

SYDRF
株式のランク #36225
Delota Corp. operates as a Canadian retail company, primarily focusing on the... Delota Corp. operates as a Canadian retail company, primarily focusing on the sale of diverse cannabis products. Their product range also encompasses various vaping and nicotine-related items, herbal vaporizers, and other smoking cessation solutions, along with their complementary accessories. The firm manages a network of 26 brick-and-mortar retail establishments complemented by an online e-commerce platform. These operations are conducted under its two prominent brands: 180 Smoke and Offside Cannabis. The company, which is headquartered in Concord, Canada, transitioned its name to Delota Corp. in November 2021, having previously been recognized as Spyder Cannabis Inc.
株価
$0.1
最終同期: 2026-08-13
時価総額
$2.91M
変化（1日）
0.00%
変化（1年）
25.00%
国
CA
取引 Delota Corp. (SYDRF)

カテゴリー

Healthcare
Delota Corp.（SYDRF）の利益
2026 時点の利益 TTM: 0
Delota Corp. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Delota Corp. の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
$1.35B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
- -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
- -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
- -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
$26.37M -
US